Lawrence Albers to Schizophrenia
This is a "connection" page, showing publications Lawrence Albers has written about Schizophrenia.
Connection Strength
0.748
-
Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs. 2008 Jan; 17(1):61-75.
Score: 0.306
-
Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem. 2004 Feb; 11(3):297-312.
Score: 0.233
-
Mercolini L, Mandrioli R, Protti M, Conca A, Albers LJ, Raggi MA. Dried blood spot testing: a novel approach for the therapeutic drug monitoring of ziprasidone-treated patients. Bioanalysis. 2014 Jun; 6(11):1487-95.
Score: 0.119
-
Reist C, Mintz J, Albers LJ, Jamal MM, Szabo S, Ozdemir V. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007 Feb; 27(1):46-51.
Score: 0.072
-
Ozdemir V, Aklillu E, Mee S, Bertilsson L, Albers LJ, Graham JE, Caligiuri M, Lohr JB, Reist C. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother. 2006 Feb; 7(2):119-33.
Score: 0.017